Evenity Dosage/Direction for Use

Dosage (dose and interval): The recommended dose of romosozumab (EVENITY) is 210 mg administered subcutaneously. To administer the 210 mg dose, give 2 subcutaneous injections of romosozumab (EVENITY). Administer romosozumab (EVENITY) once every month for 12 doses.
After completing romosozumab (EVENITY) therapy, transition to an antiresorptive osteoporosis therapy is required to preserve bone mass (see Pharmacology: Pharmacodynamics and Clinical trials under Actions).
The efficacy and safety of treatment with romosozumab (EVENITY) for longer than 12 months has not been established.
To reduce the risk of hypocalcaemia, patients should be adequately supplemented with calcium and vitamin D (see Contraindications, Precautions and Pharmacology: Pharmacodynamics: Clinical trials under Actions).
If the romosozumab (EVENITY) dose is missed, administer as soon as it can be rescheduled. Thereafter, romosozumab (EVENITY) can be scheduled every month from the date of the last dose.
The efficacy and safety of romosozumab (EVENITY) in combination with other osteoporosis treatments has not been established (see Interactions).
Method of administration: Administration should be performed by an individual who has been adequately trained in injection techniques.
To avoid discomfort at the site of injection, allow romosozumab (EVENITY) to sit at room temperature for at least 30 minutes before injecting. Do not warm in any other way. Visually inspect the solution for particles and discolouration prior to administration. Do not use if the solution is discoloured, cloudy, or contains particles. Inject the entire contents of the pre-filled syringe.
Administer romosozumab (EVENITY) in the abdomen, thigh, or upper arm subcutaneously. If using the same injection site, make sure it is not the same place on the injection site used for a previous injection. Do not inject into areas where the skin is tender, bruised, red, or hard.
Romosozumab (EVENITY) is for single-use in one patient only. Dispose of any unused medicinal product (see Special precautions for disposal under Cautions for Usage).
Dosage adjustment: Renal impairment: No dose adjustment is required in patients with renal impairment.